Long‐term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2‐year study

Documenti analoghi

• Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
  di: Apostolopoulou, S C, et al.
  Pubblicazione: (2005)
• Long‐term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease
  di: Diller, Gerhard‐Paul, et al.
  Pubblicazione: (2007)
• Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect
  di: D'Alto, M, et al.
  Pubblicazione: (2007)
• Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease
  di: Rui Baptista, et al.
  Pubblicazione: (2013-02-01)
• Efficacy and safety of Bosentan for pulmonary arterial hypertension in adults with congenital heart disease
  Pubblicazione: (2012)